Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV-alphaDC1 Vaccine for CMV Prevention After Stem Cell Transplant
NCT05589844Phase 1Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Mar 2023
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CMV-alphaDC1 in cytomegalovirus infection (CMV), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Incidence of dose limiting toxicities at 2 years, Number of multifunctional CMV antigen specific T cells at 365 days and 1 more. Planned start Mar 2023; status: withdrawn.
02
Drugs
CMV-alphaDC1
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05589844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05589844.